文献速递神经肿瘤

血清游离microRNA-214在胶质瘤中的诊断和预后潜力

Diagnostic and Prognostic Potential of Serum Cell-Free microRNA-214 in Glioma.
PubMed 文献 · World Neurosurg · 2019-02-19

该研究先证实2株胶质瘤细胞系可分泌miR-214,随后在100例术前胶质瘤患者、30例配对术后患者和100例健康对照的血清中验证游离miR-214表达。术前血清游离miR-214显著升高、术后显著下降,且与更高肿瘤级别、异柠檬酸脱氢酶缺失和甲基鸟嘌呤甲基转移酶启动子未甲基化相关,可有效区分胶质瘤与健康对照(AUC=0.885;95%CI 0.833-0.926),并为总生存期的独立预后指标。

要点

  • 胶质瘤细胞系可分泌miR-214,术前血清游离miR-214显著升高,配对术后显著下降
  • 血清游离miR-214区分胶质瘤与健康对照的AUC=0.885(95%CI 0.833-0.926)
  • 血清游离miR-214是胶质瘤总生存期的独立预后指标

核心结论

  • 血清游离miR-214有望作为胶质瘤肿瘤分层、早期诊断和预后评估的非侵入性生物标志物。

研究设计与样本

  • 筛查阶段检测2株胶质瘤细胞系培养基中miR-214表达以确认其是否可分泌。
  • 验证阶段在独立样本集中检测100例术前胶质瘤患者、30例配对术后患者和100例健康对照的血清游离miR-214表达。

主要发现

  • miR-214可由胶质瘤细胞系分泌。
  • 术前胶质瘤患者血清细胞外miR-214水平显著过表达,而配对术后血清中其表达显著下降。
  • 血清中上调的游离miR-214与更高肿瘤级别、异柠檬酸脱氢酶缺失和甲基鸟嘌呤甲基转移酶启动子未甲基化显著相关。
  • 血清细胞外miR-214可有效区分胶质瘤患者与健康对照,曲线下面积=0.885(95%CI 0.833-0.926)。
  • 血清游离miR-214是胶质瘤患者总生存期的独立预后指标。

关键数值与推荐

  • 血清游离miR-214区分胶质瘤与健康对照的曲线下面积=0.885(95%CI 0.833-0.926)。
  • 术前胶质瘤患者100例、配对术后患者30例、健康对照100例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to expound feasibility of serum cell-free microRNA-214 (miR-214) as a noninvasive biomarker for glioma in this study. PATIENTS AND METHODS: We detected expression of miR-214 in medium from 2 glioma cell lines to confirm whether it is secretory in screening phase. Then, we verified cell-free miR-214 expression in serum samples from an independent set of 100 preoperative patients with glioma, 30 matching postoperative patients, and 100 healthy controls. RESULTS: MiR-214 was secreted from glioma cell lines. Extracellular miR-214 levels were significantly overexpressed in preoperative serum from glioma patients with glioma, whereas its expression significantly decreased in matched postoperative serum. Upregulated cell-free miR-214 in serum was significantly associated with higher tumor grade, absence of isocitrate dehydrogenase, and unmethylated methylguanine methyltransferase promoter. Extracellular miR-214 in serum could effectively distinguish patients with glioma from healthy control (area under the curve = 0.885; 95% confidence interval, 0.833-0.926). Moreover, serum cell-free miR-214 was an independent prognostic indicator of overall survival for patients with glioma. CONCLUSIONS: Serum cell-free miR-214 could serve as a promising noninvasive biomarker of glioma in tumor stratification, early diagnosis, and prognostic evaluation.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wang J, Che F, Zhang J, et al. Diagnostic and Prognostic Potential of Serum Cell-Free microRNA-214 in Glioma. World Neurosurg. 2019. PMID: 30794970. doi:10.1016/j.wneu.2019.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。